These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 15704271)

  • 21. Dysglycemia and cardiovascular risk in the general population.
    Gerstein HC
    Circulation; 2009 Feb; 119(6):773-5. PubMed ID: 19221229
    [No Abstract]   [Full Text] [Related]  

  • 22. HIV as an emerging chronic disease: the challenge of "living with living".
    Daskalakis DC
    Body Posit; 2006; 19(1):8-13. PubMed ID: 16718869
    [No Abstract]   [Full Text] [Related]  

  • 23. Side effects. Using metabolomics for predicting side effects.
    TreatmentUpdate; 2005; 17(5):11-2. PubMed ID: 17219662
    [No Abstract]   [Full Text] [Related]  

  • 24. [Metabolic risk during antipsychotic treatment in patients with schizophrenia].
    Rzewuska M
    Psychiatr Pol; 2007; 41(4):457-72. PubMed ID: 18046977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Managing longterm side effects of HIV therapy. What to look for and tips to use.
    Oelklaus MW; Williams CL; Clay PG
    Posit Aware; 2007; 18(2):33-4. PubMed ID: 17390489
    [No Abstract]   [Full Text] [Related]  

  • 26. HIV and genetics. Genetic test reduces AIDS drug side effects.
    AIDS Policy Law; 2007 Aug; 22(15):1. PubMed ID: 18225348
    [No Abstract]   [Full Text] [Related]  

  • 27. Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy.
    Falutz J
    Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):651-61. PubMed ID: 17710086
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Side effects of antiretroviral therapy--skin manifestations].
    Esser S
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():8, 10-1. PubMed ID: 19024907
    [No Abstract]   [Full Text] [Related]  

  • 29. Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders.
    Tarr PE; Taffé P; Bleiber G; Furrer H; Rotger M; Martinez R; Hirschel B; Battegay M; Weber R; Vernazza P; Bernasconi E; Darioli R; Rickenbach M; Ledergerber B; Telenti A;
    J Infect Dis; 2005 May; 191(9):1419-26. PubMed ID: 15809899
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Queaze, sneeze, yawn, and runs. A little laundry list of possible side effects of the different HIV drug classes.
    Vázquez E
    Posit Aware; 2009; 20(5):27. PubMed ID: 19785105
    [No Abstract]   [Full Text] [Related]  

  • 31. Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen.
    Colafigli M; Di Giambenedetto S; Bracciale L; Tamburrini E; Cauda R; De Luca A
    HIV Med; 2008 Mar; 9(3):172-9. PubMed ID: 18217998
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term complications of antiretroviral therapy: lipoatrophy.
    Waters L; Nelson M
    Int J Clin Pract; 2007 Jun; 61(6):999-1014. PubMed ID: 17504362
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Break no bones about it. HIV itself--as well as medications and traditional causes--may increase the risk of fracture.
    Vázquez E
    Posit Aware; 2009; 20(3):40, 42-3. PubMed ID: 19492449
    [No Abstract]   [Full Text] [Related]  

  • 34. Survey also shows fear of side effects undercuts care. Treatment applauded but side effects remain.
    AIDS Alert; 2008 Sep; 23(9):105-6. PubMed ID: 18939307
    [No Abstract]   [Full Text] [Related]  

  • 35. Direct-to-consumer advertisements for HIV antiretroviral medications: a progress report.
    Kallen A; Woloshin S; Shu J; Juhl E; Schwartz L
    Health Aff (Millwood); 2007; 26(5):1392-8. PubMed ID: 17848450
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complications & side effects. Can statins be used as anti-HIV drugs?
    TreatmentUpdate; 2004; 16(7):9. PubMed ID: 17219689
    [No Abstract]   [Full Text] [Related]  

  • 37. A pilot randomized trial comparing an intensive versus a standard intervention in stable HIV-infected patients with moderate-high cardiovascular risk.
    Masiá M; Bernal E; Padilla S; García N; Escribano JC; Martínez E; Gutiérrez F
    J Antimicrob Chemother; 2009 Sep; 64(3):589-98. PubMed ID: 19625372
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Usage of stavudine (D4T) - a retrospective analysis in a South London hospital.
    Lechelt M; McCormick S; de Ruiter A
    Int J STD AIDS; 2007 Mar; 18(3):215-7. PubMed ID: 17362559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prevention and therapy of HIV-associated lipodystrophy syndrome and antiretroviral caused metabolic changes].
    Mauss S
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():49-53. PubMed ID: 16385875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dyslipidaemia and cardiovascular risk in HIV infection.
    Kulasekaram R; Peters BS; Wierzbicki AS
    Curr Med Res Opin; 2005 Nov; 21(11):1717-25. PubMed ID: 16307691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.